Natural prevalence of HCV variants with decreased sensitivity to NS3/4A protease inhibitors in HIV-1 co-infected patients treated with interferon (peg-INF) plus ribavirin (RBV) | Irsicaixa

Tamaño actual: 100%

idioma:

CONTENIDO

Natural prevalence of HCV variants with decreased sensitivity to NS3/4A protease inhibitors in HIV-1 co-infected patients treated with interferon (peg-INF) plus ribavirin (RBV)

Entidad finanzadora: Merck Sharp & Dohme

Entidad(es) participant(es): Fundació IrsiCaixa

Variabilidad genética del VIH